WO2001092299A3 - Adenovirus particles with mutagenized fiber proteins - Google Patents

Adenovirus particles with mutagenized fiber proteins Download PDF

Info

Publication number
WO2001092299A3
WO2001092299A3 PCT/EP2001/006286 EP0106286W WO0192299A3 WO 2001092299 A3 WO2001092299 A3 WO 2001092299A3 EP 0106286 W EP0106286 W EP 0106286W WO 0192299 A3 WO0192299 A3 WO 0192299A3
Authority
WO
WIPO (PCT)
Prior art keywords
fiber
proteins
particles
adenovirus particles
relates
Prior art date
Application number
PCT/EP2001/006286
Other languages
French (fr)
Other versions
WO2001092299A2 (en
WO2001092299A9 (en
Inventor
John Leonard Jakubczak
Michele Lynette Rollence
David A Stewart
Susan C Stevenson
Paul L Hallenbeck
Neeraja Idamakanti
Michael Kaleko
Theodore Smith
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
John Leonard Jakubczak
Michele Lynette Rollence
David A Stewart
Susan C Stevenson
Paul L Hallenbeck
Neeraja Idamakanti
Michael Kaleko
Theodore Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, John Leonard Jakubczak, Michele Lynette Rollence, David A Stewart, Susan C Stevenson, Paul L Hallenbeck, Neeraja Idamakanti, Michael Kaleko, Theodore Smith filed Critical Novartis Ag
Priority to AU2001283832A priority Critical patent/AU2001283832A1/en
Priority to CA002410981A priority patent/CA2410981A1/en
Priority to IL15314301A priority patent/IL153143A0/en
Priority to JP2002500910A priority patent/JP2004512015A/en
Priority to EP01962700A priority patent/EP1364038A2/en
Publication of WO2001092299A2 publication Critical patent/WO2001092299A2/en
Publication of WO2001092299A9 publication Critical patent/WO2001092299A9/en
Publication of WO2001092299A3 publication Critical patent/WO2001092299A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to mutated adenoviral fiber proteins and adenovirus particles containing such proteins. It further relates to polynucleotides encoding the proteins and vectors containing polynucleotides. It also relates to methods for making and using the adenoviral particles. With the mutated fiber proteins, the adenovirus particles no longer bind to their natural cellular receptor. They can then be 'retargeted' to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. Specific fiber mutations are listed, which ablate binding to the natural receptor. Adenovirus particles with certain fiber mutations were found to enhance gene transfer to and expression in liver as compared to viral particles with wild-type fiber.
PCT/EP2001/006286 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins WO2001092299A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001283832A AU2001283832A1 (en) 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins
CA002410981A CA2410981A1 (en) 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins
IL15314301A IL153143A0 (en) 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins
JP2002500910A JP2004512015A (en) 2000-06-02 2001-06-01 Adenovirus particles with mutated fiber proteins
EP01962700A EP1364038A2 (en) 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58534400A 2000-06-02 2000-06-02
US09/585,344 2000-06-02
US27055501P 2001-02-22 2001-02-22
US60/270,555 2001-02-22

Publications (3)

Publication Number Publication Date
WO2001092299A2 WO2001092299A2 (en) 2001-12-06
WO2001092299A9 WO2001092299A9 (en) 2002-09-19
WO2001092299A3 true WO2001092299A3 (en) 2003-09-04

Family

ID=26954360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006286 WO2001092299A2 (en) 2000-06-02 2001-06-01 Adenovirus particles with mutagenized fiber proteins

Country Status (6)

Country Link
EP (1) EP1364038A2 (en)
JP (1) JP2004512015A (en)
AU (1) AU2001283832A1 (en)
CA (1) CA2410981A1 (en)
IL (1) IL153143A0 (en)
WO (1) WO2001092299A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7611868B2 (en) 2003-05-14 2009-11-03 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Recombinant modified adenovirus fiber protein
FR2856928A1 (en) * 2003-07-04 2005-01-07 Inst Nat Sante Rech Med A NOVEL ADJUVANT COMPOUND FOR IMMUNITY, COMPOSITIONS CONTAINING SAME, AND METHODS USING THE SAME
JP4478775B2 (en) * 2003-07-31 2010-06-09 財団法人名古屋産業科学研究所 Efficient production method of growth control type recombinant adenovirus vector and kit for production thereof
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
CN113954923B (en) * 2021-11-02 2024-04-26 交控科技股份有限公司 Marshalling train parking control method and control system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007865A1 (en) * 1996-08-21 1998-02-26 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
WO1998044121A1 (en) * 1997-04-02 1998-10-08 Transgene S.A. Modified adenoviral fiber and target adenoviruses
WO1998050053A1 (en) * 1997-05-08 1998-11-12 Genetic Therapy, Inc. Gene transfer with adenoviruses having modified fiber proteins
WO2000015823A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007865A1 (en) * 1996-08-21 1998-02-26 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
WO1998044121A1 (en) * 1997-04-02 1998-10-08 Transgene S.A. Modified adenoviral fiber and target adenoviruses
WO1998050053A1 (en) * 1997-05-08 1998-11-12 Genetic Therapy, Inc. Gene transfer with adenoviruses having modified fiber proteins
WO2000015823A1 (en) * 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus

Also Published As

Publication number Publication date
JP2004512015A (en) 2004-04-22
WO2001092299A2 (en) 2001-12-06
AU2001283832A1 (en) 2001-12-11
CA2410981A1 (en) 2001-12-06
IL153143A0 (en) 2003-06-24
EP1364038A2 (en) 2003-11-26
WO2001092299A9 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
Krasnykh et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
WO2002053703A3 (en) Aav2 vectors and methods
WO2000073316A3 (en) Virus immunologic determinants
WO2005005610A3 (en) Mutant adeno-associated virus virions and methods of use thereof
WO2004027019A3 (en) Improved raav expression systems for genetic modification of specific capsid proteins
WO2010086189A3 (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2003092594A8 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
Schoggins et al. Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo
WO2005067478A3 (en) Recombinant icosahedral virus like particle production in pseudomonads
EP1452541A4 (en) Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
JP2002537816A5 (en)
WO1999036545A3 (en) Adenoviral vectors with modified capsid proteins
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
EP1471146A3 (en) A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors
WO2001092299A3 (en) Adenovirus particles with mutagenized fiber proteins
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
Nishimoto et al. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob
WO2004101799A3 (en) Broadening adenovirus tropism
AUPM710194A0 (en) Virus vector
Poulin et al. Fusion of large polypeptides to human adenovirus type 5 capsid protein IX can compromise virion stability and DNA packaging capacity
WO2004111251A3 (en) Modified fiber proteins for efficient receptor binding
WO2005026337A3 (en) Adenoviral vector for infecting cells deficient in a car receptor
WO2004108755A3 (en) Chimeric adenovirus capsid proteins
WO2002010417A3 (en) Methods and compositions for the construction and use of viral envelops as display particles
PT1165797E (en) Particles for gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-37, DESCRIPTION, REPLACED BY NEW PAGES 1-38; PAGES 38-41, CLAIMS, REPLACED BY NEW PAGES 39-42; PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/17-17/17; PAGES 1-85, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-55; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2001962700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001283832

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 153143

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 522855

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2410981

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 500910

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001962700

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001962700

Country of ref document: EP